Announcements
- Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
- Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
- Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
- Allakos Announces a Restructuring to Focus on Development of AK006
- Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
- Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
- Allakos Appoints Neil Graham to its Board of Directors
More ▼
Key statistics
On Tuesday, Allakos Inc (37Z:DEU) closed at 0.815, 2.00% above its 52-week low of 0.799, set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.803 |
---|---|
High | 0.836 |
Low | 0.799 |
Bid | 0.7832 |
Offer | 0.799 |
Previous close | 0.807 |
Average volume | 1.18k |
---|---|
Shares outstanding | 88.54m |
Free float | 86.41m |
P/E (TTM) | -- |
Market cap | 74.43m USD |
EPS (TTM) | -2.45 USD |
Data delayed at least 15 minutes, as of Jul 02 2024.
More ▼